Edgewise Therapeutics
Developer of sarcomere modulators for hypertrophic cardiomyopathy and heart failure.
$42.76
After-hours close−0.02 (−0.04%)
At close$42.78(−3.20%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 113.98%Insiders 1.08%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 107.59M · Float 79.59M · 74.0% free float
Institutions13F, as of Jun 30, 2026
236 holders · 122.63M shares · 44 new positions · 127 increased · 74 reduced · 31 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Orbimed Advisors LLC | 15.52M | 14.42% | 0 | Aug 14, 2026 |
| Paradigm Biocapital Advisors LP | 10.22M | 9.49% | +2.85M | Aug 14, 2026 |
| Ra Capital Management, L.P. | 8.39M | 7.80% | −2.04M | Aug 14, 2026 |
| BlackRock, Inc. | 6.61M | 6.14% | +133.3K | Aug 7, 2026 |
| Jupiter Topco LLC | 6.08M | 5.65% | +6.08Mnew | Aug 14, 2026 |
| FMR LLC | 5.49M | 5.10% | +4.47M | Aug 13, 2026 |
| Novo Holdings A/S | 5.35M | 4.97% | 0 | Aug 14, 2026 |
| Driehaus Capital Management LLC | 4.73M | 4.39% | +250.7K | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Orbimed Advisors LLCincl. Orbimed Capital LLC, Orbimed Capital GP Vi LLC +1 more | 14.50% | 15.25M | 13D | May 12, 2025 ↗ |
| RA Capital Management, L.P. | 9.90% | 10.43M | 13G | Nov 14, 2025 ↗ |
| Baker Bros. Advisors LP | 6.90% | 7.31M | 13G | Aug 14, 2025 ↗ |
| Paradigm BioCapital Advisors LP | 6.20% | 6.54M | 13G | Feb 17, 2026 ↗ |
| Janus Henderson Group PLC | 5.50% | 5.92M | 13G | May 15, 2026 ↗ |
| BlackRock, Inc. | 5.50% | 5.82M | 13G | Jul 17, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Orbimed Advisors LLC | director, 10 percent owner: | 443.8K | 0.41% | Apr 4, 2025 |
| Peter A. Thompson | director, 10 percent owner: | 443.8K | 0.41% | Apr 4, 2025 |
| R. Michael Carruthers | officer: Chief Financial Officer | 86.2K | 0.08% | Aug 14, 2025 |
| Kevin Koch | director, officer: President and CEO | 52.5K | 0.05% | Aug 14, 2026 |
| Behrad Derakhshan | officer: Chief Business Officer | 31.8K | 0.03% | Aug 14, 2026 |
| Alan J. Russell | director, officer: Chief Scientific Officer | 31.5K | 0.03% | Aug 14, 2026 |
| Jonathan C. Fox | director | 24.8K | 0.02% | Jul 1, 2026 |
| Badreddin Edris | director | 19.8K | 0.02% | Jan 23, 2026 |
| John R. Moore | officer: General Counsel | 17.7K | 0.02% | Aug 14, 2026 |
| Joanne M. Donovan | officer: CMO | 8.6K | 0.01% | Aug 14, 2026 |
3 ten-percent owners hold 8.33M shares by Form 4 — the 13D/G table above shows those stakes, the figure above counts officers and directors only · 2 people have not refiled in the last 18 months (13.50M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 12, 2026 | Kevin Kochdirector, officer: President and CEO | Sale · 3 lots | 17,971 | $43.68 | 52,488 |
| Aug 12, 2026 | Behrad Derakhshanofficer: Chief Business Officer | Sale · 4 lots | 5,100 | $43.81 | 31,826 |
| Aug 12, 2026 | John R. Mooreofficer: General Counsel | Sale · 4 lots | 5,016 | $43.82 | 17,697 |
| Aug 12, 2026 | Alan J. Russelldirector, officer: Chief Scientific Officer | Sale · 3 lots | 5,901 | $43.73 | 31,466 |
| Aug 13, 2026 | Joanne M. Donovanofficer: CMO | Sale | 2,919 | $43.41 | 8,625 |
| Aug 12, 2026 | Joanne M. Donovanofficer: CMO | Sale · 4 lots | 6,522 | $43.85 | 11,544 |
| Jul 1, 2026 | Alan J. Russelldirector, officer: Chief Scientific Officer | Sale · 2 lots | 200,000 | $39.41 | 24,555 |
| May 4, 2026 | Joanne M. Donovanofficer: CMO | Sale | 5,230 | $31.29 | 4,367 |
| May 5, 2026 | Joanne M. Donovanofficer: CMO | Sale | 50,000 | $38.57 | 4,367 |
| Apr 1, 2026 | Joanne M. Donovanofficer: CMO | Sale | 28,662 | $32.31 | 9,597 |
CongressHouse and Senate disclosures
Not reported.